Ensysce Biosciences to Participate in the 37th Annual ROTH Conference
Ensysce Biosciences (NASDAQ:ENSC), a clinical-stage pharmaceutical company focused on developing innovative severe pain relief solutions while minimizing opioid abuse and overdose risks, has announced its participation in the 37th Annual ROTH Conference.
The conference will take place from March 16-18, 2025, at the Laguna Cliffs Marriott Resort in Dana Point, CA. The company's leadership team, including CEO Dr. Lynn Kirkpatrick, CFO Dave Humphrey, and CCO Geoff Birkett, will be available for one-on-one investor meetings throughout the event.
Additionally, management will participate in a fireside chat on Tuesday, March 18th at 11:30am PT. Investors interested in scheduling meetings can contact Investor Relations at ENSC@mzgroup.us or their ROTH representative.
Ensysce Biosciences (NASDAQ:ENSC), una società farmaceutica in fase clinica focalizzata sullo sviluppo di soluzioni innovative per il sollievo dal dolore severo, riducendo al contempo i rischi di abuso e overdose di oppioidi, ha annunciato la sua partecipazione alla 37ª Conferenza Annuale ROTH.
La conferenza si svolgerà dal 16 al 18 marzo 2025, presso il Laguna Cliffs Marriott Resort a Dana Point, CA. Il team di leadership dell'azienda, incluso il CEO Dr. Lynn Kirkpatrick, il CFO Dave Humphrey e il CCO Geoff Birkett, sarà disponibile per incontri individuali con gli investitori durante l'evento.
Inoltre, la direzione parteciperà a un fireside chat martedì 18 marzo alle 11:30 PT. Gli investitori interessati a programmare incontri possono contattare le Relazioni con gli Investitori all'indirizzo ENSC@mzgroup.us o il loro rappresentante ROTH.
Ensysce Biosciences (NASDAQ:ENSC), una empresa farmacéutica en etapa clínica centrada en desarrollar soluciones innovadoras para el alivio del dolor severo, minimizando al mismo tiempo los riesgos de abuso y sobredosis de opioides, ha anunciado su participación en la 37ª Conferencia Anual ROTH.
La conferencia tendrá lugar del 16 al 18 de marzo de 2025, en el Laguna Cliffs Marriott Resort en Dana Point, CA. El equipo de liderazgo de la empresa, incluyendo al CEO Dr. Lynn Kirkpatrick, al CFO Dave Humphrey y al CCO Geoff Birkett, estará disponible para reuniones individuales con inversores durante el evento.
Además, la dirección participará en un fireside chat el martes 18 de marzo a las 11:30 am PT. Los inversores interesados en programar reuniones pueden contactar a Relaciones con Inversores en ENSC@mzgroup.us o a su representante de ROTH.
Ensysce Biosciences (NASDAQ:ENSC), 혁신적인 중증 통증 완화 솔루션을 개발하는 데 중점을 두고 있으며, 오피오이드 남용 및 과다 복용 위험을 최소화하는 임상 단계의 제약 회사가 제37회 연례 ROTH 컨퍼런스에 참여한다고 발표했습니다.
컨퍼런스는 2025년 3월 16일부터 18일까지 캘리포니아 다나 포인트의 라구나 클리프스 메리어트 리조트에서 개최됩니다. CEO Dr. Lynn Kirkpatrick, CFO Dave Humphrey, CCO Geoff Birkett를 포함한 회사의 리더십 팀은 행사 기간 동안 투자자와의 일대일 미팅을 위해 대기합니다.
또한 경영진은 3월 18일 화요일 오전 11시 30분 PT에 진행되는 파이어사이드 챗에 참여할 예정입니다. 미팅을 예약하고자 하는 투자자는 ENSC@mzgroup.us로 투자자 관계에 연락하거나 ROTH 대표에게 문의할 수 있습니다.
Ensysce Biosciences (NASDAQ:ENSC), une entreprise pharmaceutique en phase clinique axée sur le développement de solutions innovantes pour soulager les douleurs sévères tout en minimisant les risques d'abus et de surdose d'opioïdes, a annoncé sa participation à la 37e Conférence Annuelle ROTH.
La conférence se déroulera du 16 au 18 mars 2025 au Laguna Cliffs Marriott Resort à Dana Point, Californie. L'équipe dirigeante de l'entreprise, y compris le PDG Dr. Lynn Kirkpatrick, le CFO Dave Humphrey et le CCO Geoff Birkett, sera disponible pour des réunions individuelles avec les investisseurs tout au long de l'événement.
De plus, la direction participera à un fireside chat le mardi 18 mars à 11h30 PT. Les investisseurs intéressés à planifier des réunions peuvent contacter les Relations Investisseurs à l'adresse ENSC@mzgroup.us ou leur représentant ROTH.
Ensysce Biosciences (NASDAQ:ENSC), ein pharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung innovativer Lösungen zur Schmerzlinderung bei schweren Schmerzen konzentriert und gleichzeitig die Risiken von Opioidmissbrauch und Überdosierung minimiert, hat seine Teilnahme an der 37. jährlichen ROTH-Konferenz angekündigt.
Die Konferenz findet vom 16. bis 18. März 2025 im Laguna Cliffs Marriott Resort in Dana Point, Kalifornien, statt. Das Führungsteam des Unternehmens, einschließlich CEO Dr. Lynn Kirkpatrick, CFO Dave Humphrey und CCO Geoff Birkett, wird während der Veranstaltung für persönliche Investorenmeetings zur Verfügung stehen.
Darüber hinaus wird das Management an einem Fireside Chat am Dienstag, den 18. März um 11:30 Uhr PT teilnehmen. Investoren, die an der Vereinbarung von Meetings interessiert sind, können die Investor Relations unter ENSC@mzgroup.us oder ihren ROTH-Vertreter kontaktieren.
- None.
- None.
SAN DIEGO, CA / ACCESS Newswire / March 5, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced its participation in the 37th Annual ROTH Conference being held Sunday, March 16th to Tuesday, March 18th at the Laguna Cliffs Marriott Resort in Dana Point, CA.
Ensysce's Chief Executive Officer Dr. Lynn Kirkpatrick, Chief Financial Officer Dave Humphrey, and Chief Commercial Officer Geoff Birkett will be available to host one-on-one meetings with investors during the event. In addition, management will participate in a fireside chat on Tuesday, March 18th at 11:30am PT. Interested parties can access the fireside chat here.
To schedule a one-on-one meeting with Ensysce's management, please contact Investor Relations at ENSC@mzgroup.us or your ROTH representative.
About Ensysce Biosciences
Ensysce Biosciences is a clinical stage company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.
Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196
Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us
SOURCE: Ensysce Biosciences Inc.
View the original press release on ACCESS Newswire
FAQ
When is Ensysce Biosciences (ENSC) presenting at the ROTH Conference 2025?
How can investors schedule meetings with ENSC management at the ROTH Conference?
Which Ensysce Biosciences executives will be available at the 2025 ROTH Conference?
Where is the 37th Annual ROTH Conference being held for ENSC's presentation?
What is the main focus of Ensysce Biosciences' (ENSC) drug development?
